Question 1

What are the main strengths of investing in G1?

Accepted Answer

The main strengths of investing in GlaxoSmithKline include: Strong ESG Leadership: Sustainalytics rates ESG material risk management as "Strong" with embedded responsible business practices, Robust R&D Pipeline: 14 medicines and vaccines launching 2025-31, each with £2+ billion sales potential, Global Health Impact: Comprehensive vaccine portfolio addressing diseases from RSV to HPV across all age groups.

Question 2

What are the potential drawbacks of investing in G1?

Accepted Answer

Potential drawbacks of investing in GlaxoSmithKline include: Patent Cliff Risks: Potential revenue losses as key drug patents expire and generic competition increases, Regulatory Scrutiny: Pharmaceutical industry faces increasing pricing pressure and regulatory oversight globally, R&D Uncertainty: High development costs and clinical trial risks in bringing new medicines to market.

Question 3

What are the key financial metrics for G1?

Accepted Answer

Key financial metrics for GlaxoSmithKline include: Market Cap: $14.26 billion, Current Price: $486.02, Dividend Yield: 5.48%.

GlaxoSmithKline

Key Statistics

Valuation

Trading Info

52 Week

Dividends

Detailed View

G1

ESG Ratings